🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ray Dalio’s IMCR Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q4 2025
+9,952 Shares
Current Position
18,930 Shares
$570,740 Value

Ray Dalio's IMCR Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 18,930 shares of Immunocore Holdings plc (IMCR) worth $570,740, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Ray Dalio has initiated a new position in IMCR, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 8,978 shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Immunocore Holdings plc (IMCR) Holding Value Over Time

Track share changes against reported price movement

Quarterly Immunocore Holdings plc (IMCR) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +8,978 Add 90.21% 18,930 $30.15
Q4 2025 +9,952 New Buy 9,952 $34.71

Ray Dalio's Immunocore Holdings plc Investment FAQs

Ray Dalio first purchased Immunocore Holdings plc (IMCR) in Q4 2025, acquiring 9,952 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Immunocore Holdings plc (IMCR) for 2 quarters since Q4 2025.

Ray Dalio's largest addition to Immunocore Holdings plc (IMCR) was in Q4 2025, adding 9,952 shares worth $345,434.

According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 18,930 shares of Immunocore Holdings plc (IMCR), valued at approximately $570,740.

As of the Q1 2026 filing, Immunocore Holdings plc (IMCR) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Immunocore Holdings plc (IMCR) was 18,930 shares, as reported at the end of Q1 2026.